JP5318412B2 - アンジオポエチン様４タンパク質を使用する組成物および方法 - Google Patents

アンジオポエチン様４タンパク質を使用する組成物および方法 Download PDF

Info

Publication number
JP5318412B2
JP5318412B2 JP2007522672A JP2007522672A JP5318412B2 JP 5318412 B2 JP5318412 B2 JP 5318412B2 JP 2007522672 A JP2007522672 A JP 2007522672A JP 2007522672 A JP2007522672 A JP 2007522672A JP 5318412 B2 JP5318412 B2 JP 5318412B2
Authority
JP
Japan
Prior art keywords
angptl4
antibody
composition
human
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007522672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008507531A5 (enExample
JP2008507531A (ja
Inventor
スチュアート バンティング，
ハンス−ピーター ゲルバー，
ファン リャン シャオ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2008507531A publication Critical patent/JP2008507531A/ja
Publication of JP2008507531A5 publication Critical patent/JP2008507531A5/ja
Application granted granted Critical
Publication of JP5318412B2 publication Critical patent/JP5318412B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Animal Husbandry (AREA)
  • Cardiology (AREA)
JP2007522672A 2004-07-20 2005-07-19 アンジオポエチン様４タンパク質を使用する組成物および方法 Expired - Fee Related JP5318412B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58987504P 2004-07-20 2004-07-20
US60/589,875 2004-07-20
PCT/US2005/025650 WO2006014678A2 (en) 2004-07-20 2005-07-19 Compositions and methods of using angiopoietin-like 4 protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011184642A Division JP2011235179A (ja) 2004-07-20 2011-08-26 アンジオポエチン様４タンパク質を使用する組成物および方法

Publications (3)

Publication Number Publication Date
JP2008507531A JP2008507531A (ja) 2008-03-13
JP2008507531A5 JP2008507531A5 (enExample) 2008-08-07
JP5318412B2 true JP5318412B2 (ja) 2013-10-16

Family

ID=35787695

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007522672A Expired - Fee Related JP5318412B2 (ja) 2004-07-20 2005-07-19 アンジオポエチン様４タンパク質を使用する組成物および方法
JP2011184642A Withdrawn JP2011235179A (ja) 2004-07-20 2011-08-26 アンジオポエチン様４タンパク質を使用する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011184642A Withdrawn JP2011235179A (ja) 2004-07-20 2011-08-26 アンジオポエチン様４タンパク質を使用する組成物および方法

Country Status (18)

Country Link
US (3) US7371384B2 (enExample)
EP (1) EP1781698B1 (enExample)
JP (2) JP5318412B2 (enExample)
KR (1) KR20070061524A (enExample)
CN (1) CN101080419B (enExample)
AU (1) AU2005269758B2 (enExample)
BR (1) BRPI0513477A (enExample)
CA (1) CA2574791A1 (enExample)
DK (1) DK1781698T3 (enExample)
HU (1) HUE029170T2 (enExample)
IL (4) IL180752A0 (enExample)
LT (1) LT1781698T (enExample)
MX (1) MX2007000783A (enExample)
NO (1) NO342525B1 (enExample)
NZ (2) NZ552957A (enExample)
RU (2) RU2380411C2 (enExample)
WO (1) WO2006014678A2 (enExample)
ZA (1) ZA200701184B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
MX2007000783A (es) 2004-07-20 2007-04-09 Genentech Inc Inhibidores de proteina angiopoietina tipo 4, combinaciones y su uso.
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
AU2005269716B2 (en) * 2004-07-20 2011-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
MX2007008256A (es) * 2005-01-07 2007-12-06 Lexicon Pharmaceuticals Inc Anticuerpos monoclonales contra proteina 4 similar a angiopoyetina (angptl4).
CA2617984A1 (en) * 2005-08-19 2007-03-01 Washington University In St. Louis Methods and compositions for treating gastrointestinal radiosensitivity in a subject
US20080311107A1 (en) * 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
CA2698812A1 (en) 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
EP2344890B1 (en) * 2008-10-20 2021-08-11 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods
SG10201406420XA (en) 2009-10-14 2014-11-27 Univ Nanyang Tech Antiproliferative agent
CN106146591B (zh) 2010-01-08 2020-07-31 Ionis制药公司 血管生成素样3表达的调节
WO2011089152A1 (en) * 2010-01-20 2011-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the preservation of vascular endothelial cell barrier integrity
NO2575858T3 (enExample) * 2010-06-05 2018-05-19
US9139629B2 (en) 2010-06-05 2015-09-22 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
US9475850B2 (en) * 2010-06-05 2016-10-25 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
CA2824434A1 (en) * 2011-01-08 2012-07-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102692500B (zh) * 2011-03-21 2015-06-10 上海市肿瘤研究所 Angptl4作为血清学检测肝癌转移的标志物及其应用
CN102692496B (zh) * 2011-03-21 2015-10-28 上海市肿瘤研究所 Angptl4作为缺氧检测的标志物及其应用
CN102242198A (zh) * 2011-05-25 2011-11-16 信阳师范学院 通过angptl4基因多态性进行牛育种方法
AU2012272970A1 (en) * 2011-06-21 2014-02-06 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
EP2726493B1 (en) * 2011-07-01 2020-10-14 Monsanto Technology LLC Methods and compositions for selective regulation of protein expression
CN107536847A (zh) * 2011-08-08 2018-01-05 南洋理工大学 血管生成素样4及其在调节细胞渗漏中的用途
WO2013082667A1 (en) 2011-12-09 2013-06-13 Metabolic Pharmaceuticals Pty Ltd Use of growth hormone fragments
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
SG11201500186VA (en) 2012-07-19 2015-02-27 Univ Nanyang Tech Angiopoietin-like 4 and a method of its use in wound healing
JP2016516726A (ja) * 2013-03-15 2016-06-09 ザ・ユー・エイ・ビー・リサーチ・フアンデーシヨン ネフローゼ症候群及び関連状態の治療方法
KR102482890B1 (ko) 2013-05-01 2022-12-30 아이오니스 파마수티컬즈, 인코포레이티드 아포지질단백질 (a) 발현을 조절하는 조성물 및 방법
EP3021942A4 (en) * 2013-07-19 2017-04-19 The Regents of The University of California Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
MX383753B (es) 2013-12-24 2025-03-14 Ionis Pharmaceuticals Inc Modulación de la expresión similar a la angiopoyetina tipo 3.
US20170042870A1 (en) * 2014-02-17 2017-02-16 The Brigham And Women's Hospital, Inc. Targeted nanoparticle compositions and methods of their use to treat obesity
SI3137605T1 (sl) 2014-05-01 2021-02-26 Ionis Pharmaceuticals, Inc. Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega
SG10201805646WA (en) 2014-08-07 2018-08-30 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
CN105021827B (zh) * 2015-07-17 2016-09-28 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
RS63980B1 (sr) 2015-07-22 2023-03-31 Monsanto Technology Llc Metode i sastavi za selektivnu regulaciju ekspresije proteina
CA2999341A1 (en) 2015-11-06 2017-05-11 Ionis Pharmaceuticals, Inc. Modulating apolipoprotein (a) expression
EP3478840A1 (en) * 2016-06-29 2019-05-08 Crispr Therapeutics AG Compositions and methods for gene editing
US12024708B2 (en) 2018-11-13 2024-07-02 Lipigon Pharmaceuticals Ab ANGPTL4 oligonucleotides influencing the regulation of the fatty acid metabolism
US20220372169A1 (en) * 2019-11-06 2022-11-24 Northwestern University Inhibition of the ve-ptp phosphatase protects the kidney from ischemia-reperfusion injury
CN115175685B (zh) * 2019-12-09 2024-12-13 艾姆皮瑞克公司 用于治疗血管生成素样4(angptl4)相关疾病的寡核苷酸
CN120254294B (zh) * 2025-06-05 2025-09-09 南昌大学第一附属医院 Angptl3在乙肝相关慢加急性肝衰竭预后中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227158A (en) 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
WO1999066041A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6348350B1 (en) 1997-09-19 2002-02-19 Genentech, Inc. Ligand homologues
US20030207375A1 (en) 1997-10-24 2003-11-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1931599A (en) 1997-12-19 1999-07-12 Zymogenetics Inc. Angiopoietin homolog, dna encoding it, and method of making it
CA2322425A1 (en) 1998-03-02 1999-09-10 Millennium Pharmaceuticals, Inc. Novel fdrg protein and nucleic acid molecules and uses therefor
US20030099994A1 (en) 1998-03-02 2003-05-29 Millennium Pharamceuticals, Inc. Novel FDRG protein and nucleic acid molecules and uses therefor
JP2000026767A (ja) 1998-05-01 2000-01-25 Daikin Ind Ltd 熱硬化性粉体塗料組成物
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
WO2001057188A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001053455A2 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
JP2000308488A (ja) 1999-02-23 2000-11-07 Herikkusu Kenkyusho:Kk 血管新生に関連するタンパク質および該タンパク質をコードする遺伝子
WO2000052165A2 (en) 1999-03-04 2000-09-08 Corixa Corporation Compositions and methods for breast cancer therapy and diagnosis
DK1607402T3 (da) 1999-03-08 2007-04-16 Genentech Inc Sammensætninger og fremgangsmåder til tumorbehandling
CA2370489A1 (en) 1999-04-09 2000-10-19 Human Genome Sciences, Inc. 49 human secreted proteins
EP1171594B1 (en) 1999-04-16 2006-06-07 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
AU5979300A (en) 1999-07-02 2001-01-22 Bayer Aktiengesellschaft Angiopoietin-6 and uses thereof
WO2001005825A2 (en) 1999-07-16 2001-01-25 Hyseq, Inc. Nucleic acid sequences encoding putative angiopoietin proteins
WO2001005971A2 (en) 1999-07-20 2001-01-25 Curagen Corporation Secreted polypeptides and corresponding polynucleotides
US20030207348A1 (en) 1999-07-20 2003-11-06 Shimkets Richard A. Polypeptides and polynucleotides encoding same
AU2001233041A1 (en) 2000-01-25 2001-08-07 Hyseq, Inc. Novel nucleic acids and polypeptides
CN1315451A (zh) 2000-03-29 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人血管形成素类似因子45和编码这种多肽的多核苷酸
AU2001249929A1 (en) 2000-04-07 2001-10-23 Dana-Farber Cancer Institute Inc. Fdrg proteins and nucleic acid molecules and uses therefor
PL359653A1 (en) * 2000-06-23 2004-08-23 Schering Aktiengesellschaft Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
US6673545B2 (en) 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
CN1170850C (zh) 2000-09-19 2004-10-13 上海市肿瘤研究所 人血管生成素样蛋白和编码序列及其用途
US20030120056A1 (en) 2000-10-16 2003-06-26 Audrey Goddard TIE ligand homologues
WO2002099085A2 (en) 2001-03-27 2002-12-12 Human Genome Sciences, Inc. Human secreted proteins
EP1403367A4 (en) 2001-06-08 2005-08-17 Sankyo Co A MEDICAMENT TEST METHOD FOR TREATING OR PREVENTING DISEASES SUCH AS HYPERLIPEMIA
WO2003010205A1 (en) 2001-07-26 2003-02-06 Duke University Medical Center Genes induced by hypoxia
EP1434881A4 (en) 2001-09-17 2005-10-26 Protein Design Labs Inc METHOD FOR DIAGNOSIS OF CANCER COMPOSITIONS AND METHOD FOR SCREENING ON CANCER MODULATORS
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2460653A1 (en) 2001-11-05 2003-05-15 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040038230A1 (en) 2001-11-05 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ES2429034T3 (es) 2001-11-16 2013-11-12 Genentech, Inc. Uso de antagonistas de ANGPTL3 para el tratamiento de enfermedades hepáticas
AU2002359464A1 (en) 2001-11-30 2003-06-17 Genvec, Inc. Angiopioetin related factors
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2003103581A2 (en) 2002-06-05 2003-12-18 Genentech, Inc. Compositions and methods for liver growth and liver protection
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
CA2499791A1 (en) 2004-03-30 2005-09-30 F. Hoffmann-La Roche Ag Angptl4/fiaf as marker for ppardelta modulation
MX2007000783A (es) * 2004-07-20 2007-04-09 Genentech Inc Inhibidores de proteina angiopoietina tipo 4, combinaciones y su uso.
AU2005269716B2 (en) * 2004-07-20 2011-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
MX2007008256A (es) * 2005-01-07 2007-12-06 Lexicon Pharmaceuticals Inc Anticuerpos monoclonales contra proteina 4 similar a angiopoyetina (angptl4).

Also Published As

Publication number Publication date
LT1781698T (lt) 2016-09-26
WO2006014678A2 (en) 2006-02-09
IL218357A (en) 2015-01-29
AU2005269758B2 (en) 2011-11-03
US8633155B2 (en) 2014-01-21
NZ592973A (en) 2013-01-25
CN101080419B (zh) 2014-07-02
WO2006014678A3 (en) 2006-06-22
KR20070061524A (ko) 2007-06-13
US20060093606A1 (en) 2006-05-04
IL180752A0 (en) 2007-06-03
HK1110602A1 (en) 2008-07-18
JP2011235179A (ja) 2011-11-24
ZA200701184B (en) 2008-07-30
RU2007106075A (ru) 2008-08-27
IL218357A0 (en) 2012-04-30
IL206483A0 (en) 2010-12-30
US20070054856A1 (en) 2007-03-08
IL206483A (en) 2011-11-30
RU2009137017A (ru) 2011-04-20
CN101080419A (zh) 2007-11-28
NO342525B1 (no) 2018-06-04
NZ552957A (en) 2011-06-30
EP1781698B1 (en) 2016-07-06
EP1781698A2 (en) 2007-05-09
DK1781698T3 (en) 2016-10-03
US7371384B2 (en) 2008-05-13
RU2380411C2 (ru) 2010-01-27
HUE029170T2 (en) 2017-03-28
BRPI0513477A (pt) 2008-05-06
AU2005269758A1 (en) 2006-02-09
CA2574791A1 (en) 2006-02-09
JP2008507531A (ja) 2008-03-13
MX2007000783A (es) 2007-04-09
IL209823A0 (en) 2011-02-28
NO20070950L (no) 2007-04-12
US20100172915A1 (en) 2010-07-08

Similar Documents

Publication Publication Date Title
JP5318412B2 (ja) アンジオポエチン様４タンパク質を使用する組成物および方法
JP4947717B2 (ja) アンジオポエチン様４タンパク質のインヒビター、組み合わせ、およびそれらの使用
US7731961B1 (en) Methods of increasing muscle mass or muscle strength using antibody inhibitors of GDF-8
JP5611047B2 (ja) アクチビンレセプター様キナーゼ−１アンタゴニスト組成物とその使用方法
JP2013049725A (ja) Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
JP2009541207A (ja) 腎臓疾患を治療する方法
HK1110602B (en) Compositions and methods of using angiopoietin-like 4 protein
WO2025045139A1 (zh) 特异性识别robo2的抗体及其应用
CN120424219A (zh) 特异性结合ve-ptp的抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110826

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120607

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130306

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130612

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130625

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130710

R150 Certificate of patent or registration of utility model

Ref document number: 5318412

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees